Jazz Pharmaceuticals (JAZZ) Asset Writedowns and Impairment (2014 - 2023)

Jazz Pharmaceuticals' Asset Writedowns and Impairment history runs 6 years deep, the most recent figure standing at $61.0 million for Q4 2023.

• In Q4 2023, Asset Writedowns and Impairment changed N/A year-over-year to $61.0 million; the TTM figure through Dec 2023 stood at $194.7 million (up 45.65% YoY), while the FY2023 annual figure was $61.0 million, down 54.35% from the prior year.
• Asset Writedowns and Impairment was $61.0 million for Q4 2023 at Jazz Pharmaceuticals, down from $133.6 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $136.1 million in Q1 2020 to a low of $61.0 million in Q4 2023.
• Historically, Asset Writedowns and Impairment has averaged $110.3 million across 3 years, with a median of $133.6 million in 2022.